Navigation Links
Northwest Bio Implements Major Balance Sheet Clean-Up
Date:12/2/2011

t took the total above the ceiling. As an accounting matter, the excess securities above the ceiling were required to be valued and treated as liabilities of the Company.

On November 29, 2011, the holders of a majority of the shares of the Company's stock voted to increase the authorized ceiling from 150 million shares to 450 million shares.  When this increase is effective in several weeks, the Company's $16.6 million liability related to the insufficiency of authorized shares will be removed in its entirety.    

Linda Powers, Northwest Bio's CEO, commented that, "We are very pleased to be able to make such a major reduction in liabilities as part of our ongoing program of strengthening of our balance sheet.  With just $2.3 million of accounts payable, maintained on a current  basis and relating to the Company's accelerating 240-patient clinical trial in its lead program, and with the remaining debt in the hands of mostly long-term supporters of the Company, we are making great progress in reaching a stronger and healthier financial position. Combined with the strength of our science and our clinical trials, our programs in both the US and Europe (the two largest medical markets in the world), and our growing outreach, this major balance sheet clean-up helps to position us to move to the next market level." 

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis in both the US and Europe.  The Company has a broad platform technology for dendritic cell-based vaccines.  The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal of brain cancer.  The Company also prev
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioSpace Spotlights Northwests Life Science Community
2. Northwest Bio Announces Interview of CEO Linda Powers in Todays CEO/CFO Publication
3. NORTHWEST BIO Announces Positive Third Quarter Progress
4. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
5. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
6. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
7. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
8. Northwest Biotherapeutics Announces Change and Expansion of Management Team
9. Northwest Biotherapeutics Announces Series of Financing Arrangements
10. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
11. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... NEW YORK , August 27, 2015 ... on enhancing image processing functions in the human vision system, ... Angeles point guard Chris Paul to ... basketball players who want to improve their real-life on-court performance. ... on the court, whether it is shooting a ball or ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
(Date:8/26/2015)... Florida , August 26, 2015 ... the biggest factors fueling the optimism in biotech,s ... M&A,s, collaborations and life sciences advancements.  Active biotechnology ... are Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, Inc. ... SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: ...
Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... 29 Pharmion Corporation,(Nasdaq: PHRM ) today ... has granted Fast Track designation for oral Azacitidine ... Track programs are designed to facilitate the development ... intended to treat serious or,life-threatening conditions and that ...
... with an overview of cardiovascular genetics ... ... 29 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN),a company focused on ... virtually any disease or medical,condition, today announced that its co-founder ...
... Aug. 29 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... specialty pharmaceutical and,medical device company, today announced ... has given clearance to begin marketing the,Hemo-Stream(TM) ... developed by Rex Medical, LP, is the ...
Cached Biology Technology:Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6GeneNews' Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book 2Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 2Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 3Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 4
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... University of Bergen, Norway have deduced how bony fishes ... filling their eggs with the water of life ?the ... genes causes the eggs to fill with vital water ... extant marine teleosts that showed an unprecedented radiation during ...
... Scientists at the MIT Media Lab have invented a ... yellow light, offering the prospect of controlling the haywire ... and Parkinson's disease. , Such diseases often must be ... MIT research could lead to the development of optical ...
... , professor of molecular biophysics and biochemistry at ... Foundation to expand research on the delivery of a targeted ... and his collaborator Zhiwei Hu have developed a way to ... thus destroying the tumors while leaving normal tissue unharmed. ...
Cached Biology News:How fish conquered the ocean 2How fish conquered the ocean 3MIT: Pulsing light silences overactive neurons 2Nanoparticles for delivery of prostate cancer treatment 2
Request Info...
... StabilZyme HRP Conjugate Stabilizer is an ... protein and other non-toxic stabilizing chemicals in ... 6.2 6.7. This product contains ... and 20 ppm Proclin 300 (Rohm and ...
Preparation Note: by a modification of the procedure of C.W. Hancher et al., Biotechnol. Bioeng. 11, 1055 (1969) Assay: ~ 20 A 260 /mg Solubility: water 10 mg/mL, clear, light-yellow Suitab tst...
Request Info...
Biology Products: